Indeed, knockdown studies confirmed that targeting the glycolytic pathway for disruption results in anti-proliferative effects, specific to PIK3CA mutant cells, suggesting that this could be a therapeutic strategy for specifically targeting patients with PIK3CA mutant tumours. This evidence concerns the gene PIK3CA and neoplasm.